Profound Medical Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PROF research report →
Range $11 – $11
Price Chart
About the company
Profound Medical Corp. , along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management.
- CEO
- Arun Swarup Menawat
- IPO
- 2019
- Employees
- 162
- HQ
- Mississauga, ON, CA
Get TickerSpark's AI analysis on PROF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $233.68M
- P/E
- -7.00
- Fwd P/E
- 8.99
- PEG
- -0.19
- P/S
- 10.01
- P/B
- 5.54
- EV/EBITDA
- -6.27
- Div Yield
- 0.00%
- Gross Margin
- 73.82%
- Op Margin
- -144.15%
- Net Margin
- -136.86%
- ROE
- -59.18%
- ROIC
- -67.00%
Latest fiscal year · YoY change
- Revenue
- $16.38M+61.1%
- Gross Profit
- $11.59M+73.0%
- Op Income
- $-41,976,173
- Net Income
- $-43,315,210-63.6%
- EPS
- $-1.43-33.6%
- OCF Growth
- -65.8%
- FCF Growth
- -66.5%
- 52W High
- $8.95
- 52W Low
- $4.80
- 50D MA
- $6.35
- 200D MA
- $6.64
- Beta
- 0.53
- RSI (14)
- 43
- Avg Volume
- 208.29K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Profound posted 86% revenue growth in Q3, widened its commercial pipeline, and raised 2026 guidance while highlighting a CEO transition and new distribution partnerships.· November 5, 2026
- Q3 revenue was $9.8 million, up 86% year over year, with gross margin expanding to 78% from 74%.
- Net loss improved to about $7.7 million, or $0.21 per share, versus about $8 million, or $0.26 per share, last year.
- Cash used in operating activities fell to $5 million, down 56% sequentially and 48% year over year; cash ended the quarter at about $33.3 million.
- Full-year 2026 guidance was raised to at least $25 million in revenue with gross margin of 70% or higher.
- The company announced Richard Fabian will become CEO on January 14, 2027, while Arun Menawat moves to Executive Chair; Matthew Sobczyk was named permanent CFO.
- Cook Medical and Telix partnerships were framed as key growth drivers, with Cook expected to broaden channel access and Telix supporting physician education and imaging adoption.
For the 3 months ended September 30, 2026, total revenue was $9.8 million, up 86% from Q3 2025. Revenue included $4.1 million of recurring noncapital revenue and $5.7 million of capital equipment sales. Gross margin was 78% versus 74% in the prior-year quarter. Operating expenses were $15.5 million, up 21% year over year. Net loss improved 3% to approximately $7.7 million, or $0.21 per common share, compared with approximately $8 million, or $0.26 per share, in Q3 2025. Cash used in operating activities was $5 million, down from $11.3 million sequentially and $9.6 million a year ago; cash ended at approximately $33.3 million. Management projected full-year 2026 revenue of at least $25 million and gross margin of 70% or higher. They said existing cash and product/service revenue should fund operations and capital expenditures for at least the next 12 months, with no immediate plans to raise capital but openness to opportunistic financing.
Arun Menawat said the market is shifting in Profound’s favor, with TULSA positioned as a distinct ‘regional ablation’ category backed by clinical evidence, reimbursement progress, and a large U.S. TAM he pegged at 600,000 patients per year. He emphasized the importance of the new Cook and Telix agreements, higher CMS reimbursement, and continued payer coverage gains, and he repeatedly framed the company as moving from early adoption toward mainstream use. His tone was upbeat and confident, with a clear handoff to Rich Fabian while reiterating that Profound is on a path to profitable growth.
Matthew Sobczyk focused on the quarter’s financial improvement and balance-sheet discipline. He cited $9.8 million in revenue, 78% gross margin, and a lower operating cash burn of $5 million, and said gross margin remained supported by favorable mix and price discipline. He also highlighted $33.3 million in cash, a 12-month funding outlook from existing cash and sales, and a capital-allocation approach centered on commercial execution, efficiency, and selectively evaluating financing options to support the path to profitability.
Analysts focused on how quickly ASC and office-based opportunities could develop, especially after the CMS reimbursement update and the Cook channel. Management said the reimbursement backdrop makes the TULSA+ ASC opportunity ‘very clear and very strong,’ but also said meaningful impact is more likely in the second half of next year as Cook’s market-entry strategy is built out. Questions also probed utilization, pipeline conversion, installed systems versus sold-but-not-installed systems, and reporting cadence; management said utilization growth is being limited more by logistics and workflow than by clinical demand, the $79.2 million pipeline is predominantly systems with some consumables and service, and future reporting will become more transparent as the business scales.
The quarter showed strong top-line momentum, better gross margin, and much lower operating cash use, while the company still sees room to expand through new channels and reimbursement tailwinds. Management believes Cook Medical, Telix, broader payer coverage, and growing installed-base utilization can accelerate recurring revenue and move the business toward profitable growth.
Management acknowledged that utilization growth depends on execution-heavy factors like logistics, scheduling, training, referral development, and customer support rather than just demand or reimbursement. They also said the Cook opportunity is still early and that material impact likely won’t show up until the second half of next year, while SG&A may fluctuate quarter to quarter as the company adds resources before they become productive.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.0%
- Shares Outstanding
- 36.63M
- Float Shares
- 35.51M
of shares held by institutions
61 13F filers
Congressional trading
Senate and House stock disclosures for PROF, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fil Ltd | 2.40M | ▲ 25.00K |
| Gagnon Securities LLC | 2.05M | ▲ 90.51K |
| Royce & Associates LP | 1.21M | ▲ 12.30K |
| Timelo Investment Management Inc. | 1.01M | ▼ 101.00K |
| Gagnon Advisors, LLC | 962.19K | 0 |
| Letko, Brosseau & Associates Inc | 935.73K | 0 |
| Rosalind Advisors, Inc. | 828.12K | 0 |
| Z3 Capital Partners, LLC | 783.14K | ▼ 37.80K |
| Mmcap International Inc. Spc | 671.36K | 0 |
| Ardsley Advisory Partners LP | 575.00K | 0 |
| Lagoda Investment Management, L.P. | 536.90K | ▲ 35.58K |
| Royal Bank Of Canada | 492.61K | ▲ 1.11K |
Held by 2 ETFs
Biggest fund positions in PROF by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 16, 25 | Menawat Arun Swarup | buy | 12,027 |
| May 15, 25 | Menawat Arun Swarup | buy | 10,003 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PROF coverage
Recent articles, reports, and earnings notes.
No research on PROF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PROF report →Profound Medical to Participate in the Stifel 2026 Healthcare Conference
globenewswire.com · Nov 9
What Profound Medical (PROF) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth
globenewswire.com · Nov 5
Profound Medical (PROF) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com · Nov 5
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade
zacks.com · Oct 30
Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
globenewswire.com · Oct 30
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar
globenewswire.com · Oct 22
Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?
zacks.com · Oct 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.